<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/journal?journal=bmcdermatol&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Dermatology - Latest Articles</title>
        <link>http://www.biomedcentral.com/bmcdermatol/</link>
        <description>The latest research articles published by BMC Dermatology</description>
        <dc:date>2013-05-16T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/13/7" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/13/6" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/13/4" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/13/5" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/13/3" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/13/2" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/13/1" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/12/21" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/12/20" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/12/19" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/13/7">
        <title>Improved emollient use reduces atopic eczema symptoms and is cost neutral in infants: before-and-after evaluation of a multifaceted educational support programme</title>
        <description>Background  Parents and carers of children with eczema often underuse emollient therapy, essential to repairing and protecting the defective skin barrier in atopic eczema.  Educational interventions delivered by specialist dermatology nurses in hospital settings have been shown to improve emollient use and reduce symptoms of atopic eczema, but benefits of community-based interventions are uncertain. Support and information about appropriate care may often be inadequate for patients and carers in the community.Methods  A multifaceted educational support programme was evaluated as a method of  increasing emollient use and reducing atopic eczema in children. Support provided for parents and carers included an educational DVD, online daily diary and telephone helpline.  The before and after study included 136 British children and their parents, providing baseline and 12 week follow-up data while receiving the programme.  Measures included emollient use, POEM and PEST scores, and cost of care.Results  Average emollient use increased by 87.6g (95%CI: 81.9 to 119.5g, p=0.001) from baseline with the change being immediate and persistent. The POEM score reduced on average by 5.38 (95%CI: 4.36 to 6.41, p=0.001), a 47% reduction from baseline. Similarly the PEST score reduced on average by 0.61 (95%CI: 0.47 to 0.75, p=0.001), a 48% reduction from baseline.  Sleep disturbance was reduced by 1.27 nights per week (95%CI: 0.85 to 1.68, p=0.001) and parental feeling of control improved by 1.32 points (95%CI: 1.16 to 1.48, p=0.001). From the NHS perspective, the programme was cost neutral overall within the study period.Conclusion A community-based multifaceted educational support programme greatly increased emollient use, reducing symptoms of atopic eczema and general practitioner contacts, without increasing cost.  Significant benefits may accrue to the families and carers of children with atopic eczema due to improved sleep patterns and greater feeling of control. PEST, a new simple measure of acute and remitting atopic eczema severity designed to help parents and children to monitor and manage eczema, merits further evaluation.</description>
        <link>http://www.biomedcentral.com/1471-5945/13/7</link>
                <dc:creator>James Mason</dc:creator>
                <dc:creator>Julie Carr</dc:creator>
                <dc:creator>Carolyn Buckley</dc:creator>
                <dc:creator>Steve Hewitt</dc:creator>
                <dc:creator>Phillip Berry</dc:creator>
                <dc:creator>Josh Taylor</dc:creator>
                <dc:creator>Michael Cork</dc:creator>
                <dc:source>BMC Dermatology 2013, null:7</dc:source>
        <dc:date>2013-05-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-13-7</dc:identifier>
                                <prism:require>/content/figures/1471-5945-13-7-toc.gif</prism:require>
                <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2013-05-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/13/6">
        <title>Exposure to indoor tanning in France: a population based study</title>
        <description>Background:
Tanning lamp sessions have increased in Europe in recent years. Recent epidemiological studies have confirmed a proven link between melanoma and artificial UV exposure. However, in France, little information is available to determine the exposure of the population. This article presents the results from the &apos;Barometre cancer 2010&apos; concerning the proportion of users exposed to artificial UV radiation in France, their characteristics and level of information on the risks associated.
Methods:
A two stage random sampling telephone survey assisted by CATI system (household, individual) was performed from 3 April 2010 to 7 August 2010 on a sample of 3,359 people aged 15 to 75 years old.
Results:
In 2010, 13.4% of the French population reported to have tanning lamp sessions at least once in their lifetime and 3.5% of the total population reported the use of artificial UV radiation over the last twelve months. Exposure over the last twelve months is most commonly seen among females (5.0%) and young population between 20--25 years old (9.6%). In addition, 3.5% of those under 18 years report having attended UV booths at least once during their lifetime even though they are forbidden to minors. Moreover, more than one the third of users reported more than 10 exposures within a year. The places of exposure cited most often were beauty salons (50%) and tanning centers (46%). Only 49.2% of those surveyed felt that they were well informed on the risks of cancer associated with UV booths. Furthermore, the population was found to have misconceptions about artificial UV radiation. One quarter of the population, believe that artificial UV radiation use before vacation protects the skin from sunburn.
Conclusions:
This first study on artificial UV radiation exposure in France has better quantified and characterized the users. It has also defined the state of knowledge and the perception of risk by the general French population. This work will contribute to determine actions of prevention to reduce cancer risk related to artificial UV radiation.</description>
        <link>http://www.biomedcentral.com/1471-5945/13/6</link>
                <dc:creator>Tarik Benmarhnia</dc:creator>
                <dc:creator>Christophe Léon</dc:creator>
                <dc:creator>François Beck</dc:creator>
                <dc:source>BMC Dermatology 2013, null:6</dc:source>
        <dc:date>2013-04-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-13-6</dc:identifier>
                                <prism:require>/content/figures/1471-5945-13-6-toc.gif</prism:require>
                <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2013-04-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/13/4">
        <title>BMC Dermatology reviewer acknowledgement, 2012</title>
        <description>Contributing reviewersThe editors of BMC Dermatology would like to thank all our reviewers who have contributed to the journal in Volume 12 (2012).</description>
        <link>http://www.biomedcentral.com/1471-5945/13/4</link>
                <dc:creator>Hayley Henderson</dc:creator>
                <dc:source>BMC Dermatology 2013, null:4</dc:source>
        <dc:date>2013-04-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-13-4</dc:identifier>
                                <prism:require>/content/figures/1471-5945-13-4-toc.gif</prism:require>
                <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2013-04-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/13/5">
        <title>Single application of 4% dimeticone liquid gel versus two applications of 1% permethrin creme rinse for treatment of head louse infestation: a randomised controlled trial</title>
        <description>Background:
A previous study indicated that a single application of 4% dimeticone liquid gel was effective in treating head louse infestation. This study was designed to confirm this in comparison with two applications of 1% permethrin.
Methods:
We have performed a single centre parallel group, randomised, controlled, open label, community based trial, with domiciliary visits, in Cambridgeshire, UK. Treatments were allocated through sealed instructions derived from a computer generated list. We enrolled 90 children and adults with confirmed head louse infestation analysed by intention to treat (80 per-protocol after 4 drop outs and 6 non-compliant). The comparison was between 4% dimeticone liquid gel applied once for 15 minutes and 1% permethrin creme rinse applied for 10 minutes, repeated after 7 days as per manufacturer&#8217;s directions. Evaluated by elimination of louse infestation after completion of treatment application regimen.
Results:
Intention to treat comparison of a single dimeticone liquid gel treatment with two of permethrin gave success for 30/43 (69.8%) of the dimeticone liquid gel group and 7/47 (14.9%) of the permethrin creme rinse group (OR 13.19, 95% CI 4.69 to 37.07) (p&#8201;&lt;&#8201;0.001). Per protocol results were similar with 27/35 (77.1%) success for dimeticone versus 7/45 (15.6%) for permethrin. Analyses by household gave essentially similar outcomes.
Conclusions:
The study showed one 15 minute application of 4% dimeticone liquid gel was superior to two applications of 1% permethrin creme rinse (p&#8201;&lt;&#8201;0.001). The low efficacy of permethrin suggests it should be withdrawn.Trial registrationCurrent Controlled Trials ISRCTN88144046.</description>
        <link>http://www.biomedcentral.com/1471-5945/13/5</link>
                <dc:creator>Ian Burgess</dc:creator>
                <dc:creator>Elizabeth Brunton</dc:creator>
                <dc:creator>Nazma Burgess</dc:creator>
                <dc:source>BMC Dermatology 2013, null:5</dc:source>
        <dc:date>2013-04-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-13-5</dc:identifier>
                                <prism:require>/content/figures/1471-5945-13-5-toc.gif</prism:require>
                <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2013-04-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/13/3">
        <title>Barriers and facilitators of adherence to medical advice on skin self-examination during melanoma follow-up care</title>
        <description>Background:
Melanoma is the fastest growing tumor of the skin, which disproportionately affects younger and middle-aged adults. As melanomas are visible, recognizable, and highly curable while in early stages, early diagnosis is one of the most effective measures to decrease melanoma-related mortality. Skin self-examination results in earlier detection and removal of the melanoma. Due to the elevated risk of survivors for developing subsequent melanomas, monthly self-exams are strongly recommended as part of follow-up care. Yet, only a minority of high-risk individuals practices systematic and regular self-exams. This can be improved through patient education. However, dermatological education is effective only in about 50% of the cases and little is known about those who do not respond. In the current literature, psychosocial variables like distress, coping with cancer, as well as partner and physician support are widely neglected in relation to the practice of skin self-examination, despite the fact that they have been shown to be essential for other health behaviors and for adherence to medical advice. Moreover, the current body of knowledge is compromised by the inconsistent conceptualization of SSE. The main objective of the current project is to examine psychosocial predictors of skin self-examination using on a rigorous and clinically sound methodology.Methods/DesignThe longitudinal, mixed-method study examines key psychosocial variables related to the acquisition and to the long-term maintenance of skin self-examination in 200 patients with melanoma. Practice of self-exam behaviors is assessed at 3 and 12&#8201;months after receiving an educational intervention designed based on best-practice standards. Examined predictors of skin self-exam behaviors include biological sex, perceived self-exam efficacy, distress, partner and physician support, and coping strategies. Qualitative analyses of semi-structured interviews will complement and enlighten the quantitative findings.DiscussionThe identification of short and long-term predictors of skin self-examination and an increased understanding of barriers will allow health care professionals to better address patient difficulties in adhering to this life-saving health behavior. Furthermore, the findings will enable the development and evaluation of evidence-based, comprehensive intervention strategies. Ultimately, these findings could impact a wide range of outreach programs and secondary prevention initiatives for other populations with increased melanoma risk.</description>
        <link>http://www.biomedcentral.com/1471-5945/13/3</link>
                <dc:creator>Annett Körner</dc:creator>
                <dc:creator>Martin Drapeau</dc:creator>
                <dc:creator>Brett Thombs</dc:creator>
                <dc:creator>Zeev Rosberger</dc:creator>
                <dc:creator>Beatrice Wang</dc:creator>
                <dc:creator>Manish Khanna</dc:creator>
                <dc:creator>Alan Spatz</dc:creator>
                <dc:creator>Adina Coroiu</dc:creator>
                <dc:creator>Rosalind Garland</dc:creator>
                <dc:creator>Gerald Batist</dc:creator>
                <dc:source>BMC Dermatology 2013, null:3</dc:source>
        <dc:date>2013-03-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-13-3</dc:identifier>
                                <prism:require>/content/figures/1471-5945-13-3-toc.gif</prism:require>
                <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2013-03-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/13/2">
        <title>TGF&#223; signaling regulates lipogenesis in human sebaceous glands cells</title>
        <description>Background:
Sebaceous glands are components of the skin essential for its normal lubrication by the production of sebum. This contributes to skin health and more importantly is crucial for the skin barrier function. A mechanistic understanding of sebaceous gland cells growth and differentiation has lagged behind that for keratinocytes, partly because of a lack of an in vitro model that can be used for experimental manipulation.
Methods:
We have developed an in vitro culture model to isolate and grow primary human sebocytes without transformation that display functional characteristics of sebocytes. We used this novel method to probe the effect of Transforming Growth Factor &#946; (TGF&#946;) signaling on sebocyte differentiation, by examining the expression of genes involved in lipogenesis upon treatment with TGF&#946;1. We also repressed TGF&#946; signaling through knockdown of the TGF&#946; Receptor II to address if the effect of TGF&#946; activation is mediated via canonical Smad signal transduction.
Results:
We find that activation of the TGF&#946; signaling pathway is necessary and sufficient for maintaining sebocytes in an undifferentiated state. The presence of TGF&#946; ligand triggered decreased expression in genes required for the production of characteristics sebaceous lipids and for sebocyte differentiation such as FADS2 and PPAR&#947;, thereby decreasing lipid accumulation through the TGF&#946; RII-Smad2 dependent pathway.
Conclusion:
TGF&#946; signaling plays an essential role in sebaceous gland regulation by maintaining sebocytes in an undifferentiated state. This data was generated using a novel method for human sebocyte culture, which is likely to prove generally useful in investigations of sebaceous gland growth and differentiation. These findings open a new paradigm in human skin biology with important implications for skin therapies.</description>
        <link>http://www.biomedcentral.com/1471-5945/13/2</link>
                <dc:creator>Adrian McNairn</dc:creator>
                <dc:creator>Yanne Doucet</dc:creator>
                <dc:creator>Julien Demaude</dc:creator>
                <dc:creator>Marion Brusadelli</dc:creator>
                <dc:creator>Christopher Gordon</dc:creator>
                <dc:creator>Armando Uribe-Rivera</dc:creator>
                <dc:creator>Paul Lambert</dc:creator>
                <dc:creator>Charbel Bouez</dc:creator>
                <dc:creator>Lionel Breton</dc:creator>
                <dc:creator>Géraldine Guasch</dc:creator>
                <dc:source>BMC Dermatology 2013, null:2</dc:source>
        <dc:date>2013-01-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-13-2</dc:identifier>
                                <prism:require>/content/figures/1471-5945-13-2-toc.gif</prism:require>
                <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2013-01-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/13/1">
        <title>Calciphylaxis &#191; a challenging &amp; solvable task for plastic surgery? A case report</title>
        <description>Background:
Calciphylaxis (calcific uremic arteriolopathy) is rare and its pathogenesis is not fully understood. Indeed, Calciphylaxis presents a challenge through the course of its management which involve different specialities but unfortunately this disease so far has a poor prognosis. We herein present, in this case report, a multidisciplinary approach involving plastic surgeons with special regards to reconstructive approach after debridement procedures.Case presentationWe present a 21 years old male with a BMI of 38,2, who was transferred to our department from another hospital. Calciphylaxis has been diagnosed after receiving anticoagulation with phenprocoumon after a single event of pulmonary embolism. The INR on admission was 1,79. He had necrotic spots on both sides of the abdominal wall and on both thighs medially. During this time he underwent several reconstructive procedures in our department.
Conclusion:
It can be suggested that this agonizing disease needs indeed a multidisciplinary approach involving Nephrologists, Dermatologists, Intensive Care Physicians and Plastic Surgeons, taking into consideration that surgical correction can achieve further improvement in a specialized centre. Notwithstanding, further cohort studies should be approached clinically to insight the light on this disease with special regard to the prognosis after this approach.</description>
        <link>http://www.biomedcentral.com/1471-5945/13/1</link>
                <dc:creator>Savas Tsolakidis</dc:creator>
                <dc:creator>Gerrit Grieb</dc:creator>
                <dc:creator>Andrzej Piatkowski</dc:creator>
                <dc:creator>Ziyad Alharbi</dc:creator>
                <dc:creator>Erhan Demir</dc:creator>
                <dc:creator>David Simons</dc:creator>
                <dc:creator>Norbert Pallua</dc:creator>
                <dc:source>BMC Dermatology 2013, null:1</dc:source>
        <dc:date>2013-01-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-13-1</dc:identifier>
                                <prism:require>/content/figures/1471-5945-13-1-toc.gif</prism:require>
                <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2013-01-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/12/21">
        <title>Sentinel lymph node biopsy in melanoma: Our 8-year clinical experience in a single French institute (2002&#191;2009)</title>
        <description>Background:
Since the introduction of sentinel lymph node biopsy (SLNB), its use as a standard of care for patients with clinically node-negative cutaneous melanoma remains controversial. We wished to evaluate our experience of SLNB for melanoma.
Methods:
A single center observational cohort of 203 melanoma patients with a primary cutaneous melanoma (tumour thickness&#8201;&gt;&#8201;1 mm) and without clinical evidence of metastasis was investigated from 2002 to 2009. Head and neck melanoma were excluded. SLN was identified following preoperative lymphoscintigraphy and intraoperative gamma probe interrogation.
Results:
The SLN identification rate was 97%. The SLN was tumor positive in 44 patients (22%). Positive SLN was significantly associated with primary tumor thickness and microscopic ulceration. The median follow-up was 39.5 (5&#8211;97) months. Disease progression was significantly more frequent in SLN positive patients (32% vs 13%, p&#8201;=&#8201;0.002). Five-year DFS and OS of the entire cohort were 79.6% and 84.6%, respectively, with a statistical significant difference between SLN positive (58.7% and 69.7%) and SLN negative (85% and 90.3%) patients (p&#8201;=&#8201;0.0006 and p&#8201;=&#8201;0.0096 respectively). Postoperative complications after SLNB were observed in 12% of patients.
Conclusion:
Our data confirm previous studies and support the clinical usefulness of SLNB as a reliable and accurate staging method in patients with cutaneous melanoma. However, the benefit of additional CLND in patients with positive SLN remains to be demonstrated.</description>
        <link>http://www.biomedcentral.com/1471-5945/12/21</link>
                <dc:creator>Caroline Biver-Dalle</dc:creator>
                <dc:creator>Eve Puzenat</dc:creator>
                <dc:creator>Marc Puyraveau</dc:creator>
                <dc:creator>Delphine Delroeux</dc:creator>
                <dc:creator>Hatem Boulahdour</dc:creator>
                <dc:creator>Frances Sheppard</dc:creator>
                <dc:creator>Fabien Pelletier</dc:creator>
                <dc:creator>Philippe Humbert</dc:creator>
                <dc:creator>François Aubin</dc:creator>
                <dc:source>BMC Dermatology 2012, null:21</dc:source>
        <dc:date>2012-12-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-12-21</dc:identifier>
                                <prism:require>/content/figures/1471-5945-12-21-toc.gif</prism:require>
                <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>21</prism:startingPage>
        <prism:publicationDate>2012-12-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/12/20">
        <title>Trends in lipid profiles in patients with psoriasis: a population-based analysis</title>
        <description>Background:
Psoriasis is associated with an atherogenic lipid profile but longitudinal changes in lipids around disease onset are unknown. The purpose of our study is to examine the effect of psoriasis onset on serum lipid profiles.
Methods:
We compared changes in lipid profiles in a population based incident cohort of 689 patients with psoriasis and 717 non-psoriasis subjects. All lipid measures performed 5 years before and after psoriasis incidence/index date were abstracted. Random-effects models adjusting for age, sex and calendar year were used to examine trends in lipid profiles.
Results:
There were significant declines in total cholesterol (TC) and low-density lipoprotein (LDL) levels during the 5 years before and after psoriasis incidence/index date in both the psoriasis and the non-psoriasis cohorts, with a greater decrease noted in the TC levels (p=0.022) and LDL (p=0.054) in the non-psoriasis cohort. High-density lipoprotein (HDL) levels increased significantly both before and after psoriasis incidence date in the psoriasis cohort. Triglyceride (TG) levels were significantly higher (p&lt;0.001), and HDL levels significantly lower (p=0.013) in patients with psoriasis compared to non-psoriasis subjects. There were no differences in prescriptions for lipid lowering drugs between the two cohorts.
Conclusions:
Patients with psoriasis had a significant decrease in TC and LDL levels during the 5 years before psoriasis incidence. Higher mean TG and lower mean HDL levels were noted in the 5 years before psoriasis incidence. These changes are unlikely to be caused by lipid lowering treatment alone and require further exploration.</description>
        <link>http://www.biomedcentral.com/1471-5945/12/20</link>
                <dc:creator>Bharath Manu Akkara Veetil</dc:creator>
                <dc:creator>Eric Matteson</dc:creator>
                <dc:creator>Hilal Maradit-Kremers</dc:creator>
                <dc:creator>Marian McEvoy</dc:creator>
                <dc:creator>Cynthia Crowson</dc:creator>
                <dc:source>BMC Dermatology 2012, null:20</dc:source>
        <dc:date>2012-10-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-12-20</dc:identifier>
                                <prism:require>/content/figures/1471-5945-12-20-toc.gif</prism:require>
                <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>20</prism:startingPage>
        <prism:publicationDate>2012-10-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/12/19">
        <title>What determines patient preferences for treating low risk basal cell carcinoma when comparing surgery vs imiquimod? A discrete choice experiment survey from the SINS trial</title>
        <description>Background:
The SINS trial (Controlled Clinical Trials ISRCTN48755084; Eudract No. 2004-004506-24) is a randomised controlled trial evaluating long term success of excisional surgery vs. imiquimod 5% cream for low risk nodular and superficial basal cell carcinoma (BCC). The trial included a discrete choice experiment questionnaire to explore patient preferences of a cream versus surgery for the treatment of their skin cancer.
Methods:
The self-completed questionnaire was administered at baseline to 183 participants, measuring patients&#8217; strength of preferences when choosing either alternative &#8216;surgery&#8217; or &#8216;imiquimod cream&#8217; instead of a fixed &#8216;current situation&#8217; option (of surgical excision as standard practice in UK). The treatments were described according to: cost, chance of complete clearance, side effects and appearance. Participants had to choose between various scenarios. Analysis was performed using a mixed logit model, which took into account the impact of previous BCC treatment and sample preference variability.
Results:
The analysis showed that respondents preferred &#8216;imiquimod cream&#8217; to their &#8216;current situation&#8217; or &#8216;surgery&#8217;, regardless of previous experience of BCC symptoms and treatment. Respondents were more likely to be worried about their cosmetic outcomes and side effects they might experience over and above their chance of clearance and cost. Those with no experience of surgery (compared with experience) valued more the choice of &#8216;imiquimod cream&#8217; (&#163;1013 vs &#163;781). All treatment characteristics were significant determinants of treatment choice, and there was significant variability in the population preferences for all of them.
Conclusions:
Patients with BCC valued more &#8216;imiquimod cream&#8217; than alternative &#8216;surgery&#8217; options, and all treatment characteristics were important for their choice of care. Understanding how people with a BCC value alternative interventions may better inform the development of health care interventions.</description>
        <link>http://www.biomedcentral.com/1471-5945/12/19</link>
                <dc:creator>Michela Tinelli</dc:creator>
                <dc:creator>Mara Ozolins</dc:creator>
                <dc:creator>Fiona Bath-Hextall</dc:creator>
                <dc:creator>Hywel Williams</dc:creator>
                <dc:source>BMC Dermatology 2012, null:19</dc:source>
        <dc:date>2012-10-04T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-12-19</dc:identifier>
                                <prism:require>/content/figures/1471-5945-12-19-toc.gif</prism:require>
                <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>19</prism:startingPage>
        <prism:publicationDate>2012-10-04T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
